{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Haleos Labs Limited
Haleos Labs Limited is Rated Sell by MarketsMOJO
Haleos Labs Limited is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed below reflect the company’s current position as of 26 August 2026, providing investors with the most recent and relevant data to assess the stock’s outlook.
Haleos Labs Limited is Rated Sell
Haleos Labs Limited is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 15 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Haleos Labs Falls 4.66%: Quarterly Profit Drop and Market Pressure Weigh on Shares
Haleos Labs Limited experienced a challenging week as its share price declined by 4.66% to close at Rs.1,454.05 on 7 August 2026, underperforming the Sensex which gained 1.13% over the same period. The stock’s volatility was driven primarily by the release of disappointing quarterly results on 5 August, which revealed a 36% plunge in profit amid falling revenues and rising interest expenses, triggering investor caution and a downgrade to a Sell rating.
Are Haleos Labs Limited latest results good or bad?
Haleos Labs Limited's latest results are concerning, showing an 11.59% decline in net sales and a 36.30% drop in net profit year-on-year, indicating significant operational challenges and pressure on profitability. The company needs to address these issues to stabilize performance.
Haleos Labs Limited Reports Sharp Decline in Quarterly Financials Amid Market Pressure
Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a significant deterioration in its financial performance for the quarter ended June 2026. The company’s latest results reveal steep declines in profitability and sales, marking a shift from its previous trend and prompting a downgrade in its Mojo Grade to Sell.
Haleos Labs Q1 FY27: Profit Plunges 36% Amid Revenue Decline and Margin Pressure
Haleos Labs Limited reported a disappointing first quarter for FY27, with consolidated net profit declining 36.30% year-on-year to ₹2.65 crores from ₹4.16 crores in Q1 FY26. The micro-cap pharmaceutical company, with a market capitalisation of ₹469.00 crores, saw its stock tumble 10.18% following the results announcement, closing at ₹1,421.75 on August 5, 2026.
Haleos Labs Limited is Rated Sell
Haleos Labs Limited is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Haleos Labs Limited is Rated Sell
Haleos Labs Limited is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Haleos Labs Limited is Rated Sell
Haleos Labs Limited is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Haleos Labs Limited is Rated Sell
Haleos Labs Limited is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 July 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trend, and technical outlook.
Haleos Labs Limited is Rated Sell
Haleos Labs Limited is rated Sell by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 June 2026, providing investors with the most recent and relevant data to assess the company’s outlook.
Haleos Labs Plummets 20.05% Amid Financial Setbacks and Heavy Selling Pressure
Haleos Labs Limited experienced a turbulent week ending 5 June 2026, with its stock price plunging 20.05% from Rs.1,689.95 to Rs.1,351.10, sharply underperforming the Sensex which declined a modest 0.78%. The steep fall was driven by a combination of disappointing quarterly financial results and intense selling pressure culminating in a lower circuit hit on 1 June. Despite some technical support from longer-term moving averages, the stock faced sustained weakness amid subdued liquidity and negative sentiment.
Haleos Labs Limited is Rated Sell
Haleos Labs Limited is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 June 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Haleos Labs Limited Locks at Lower Circuit With 9.8% Loss — Sellers Queue, No Buyers in Sight
At Rs 1,426.5, sellers were still queuing — but there were no buyers willing to take the other side. Haleos Labs Limited locked at its lower circuit of 9.79% on 1 Jun 2026, with unfilled sell orders and a frozen price.
Haleos Labs Limited Faces Sharp Financial Downturn Amidst Strong Market Returns
Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a significant deterioration in its financial performance for the quarter ended March 2026. Despite the company’s shares outperforming the broader market indices over multiple time horizons, key profitability and revenue metrics have taken a marked downturn, signalling challenges ahead for investors.
Are Haleos Labs Limited latest results good or bad?
Haleos Labs Limited's latest Q4 FY26 results are concerning, with a 15.68% decline in net sales and an 85.19% drop in net profit, indicating significant operational challenges and margin pressures. The company's profitability metrics have deteriorated, raising concerns about sustainability and investor confidence.
Haleos Labs Q4 FY26: Sharp Profit Decline Raises Concerns Despite Revenue Resilience
Haleos Labs Limited reported a consolidated net profit of ₹0.44 crores for Q4 FY26, representing a dramatic decline of 93.35% quarter-on-quarter and 85.19% year-on-year, raising serious questions about the pharmaceutical company's operational efficiency and profitability trajectory. The micro-cap company, with a market capitalisation of ₹517.00 crores, saw its shares trade at ₹1,689.95 on May 29, 2026, up 3.68% from the previous close, suggesting investors may be looking past the disappointing quarterly performance towards potential recovery prospects.
Haleos Labs Limited is Rated Hold
Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 Apr 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 28 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and market performance.
Haleos Labs Limited Technical Momentum Shifts Signal Bullish Outlook Amid Mixed Indicators
Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish trend. Despite some bearish signals on the weekly and monthly RSI, the stock’s overall technical indicators suggest a strengthening upward trajectory, supported by robust moving averages and bullish MACD readings. This nuanced technical landscape offers investors a complex but promising outlook on the stock’s near-term potential.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
